You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Pharma & Healthcare

Global Autologous Matrix-induced Chondrogenesis Market Research Report 2021 Professional Edition

Market Analysis and Insights: Global Autologous Matrix-induced Chondrogenesis Market
The research report studies the Autologous Matrix-induced Chondrogenesis market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Autologous Matrix-induced Chondrogenesis market size is projected to reach US$ 149.5 million by 2027, from US$ 103.9 million in 2020, at a CAGR of 4.9% during 2021-2027.
Global Autologous Matrix-induced Chondrogenesis Scope and Segment
The global Autologous Matrix-induced Chondrogenesis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Autologous Matrix-induced Chondrogenesis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Hyaluronic Acid
Collagen
Polyethylene Glycol (PEG)
Poly Lactic-Co-Glycolic Acid (PGLA)
by Application, this report covers the following segments
Knees Joint
Other
Global Autologous Matrix-induced Chondrogenesis market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Autologous Matrix-induced Chondrogenesis key players in this market include:
JRI Orthopaedics Ltd
BioTissue
Anika Therapeutics
B. Braun Melsungen
Arthro-Kinetics
Geistlich Pharma
CartiHeal
Matricel
Smith & Nephew
Zimmer Biomet Holdings
1 Market Overview of Autologous Matrix-induced Chondrogenesis
1.1 Autologous Matrix-induced Chondrogenesis Market Overview
1.1.1 Autologous Matrix-induced Chondrogenesis Product Scope
1.1.2 Autologous Matrix-induced Chondrogenesis Market Status and Outlook
1.2 Global Autologous Matrix-induced Chondrogenesis Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Autologous Matrix-induced Chondrogenesis Market Size by Region (2016-2027)
1.4 Global Autologous Matrix-induced Chondrogenesis Historic Market Size by Region (2016-2021)
1.5 Global Autologous Matrix-induced Chondrogenesis Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Autologous Matrix-induced Chondrogenesis Market Size (2016-2027)
1.6.1 North America Autologous Matrix-induced Chondrogenesis Market Size (2016-2027)
1.6.2 Europe Autologous Matrix-induced Chondrogenesis Market Size (2016-2027)
1.6.3 Asia-Pacific Autologous Matrix-induced Chondrogenesis Market Size (2016-2027)
1.6.4 Latin America Autologous Matrix-induced Chondrogenesis Market Size (2016-2027)
1.6.5 Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Size (2016-2027)

2 Autologous Matrix-induced Chondrogenesis Market Overview by Type
2.1 Global Autologous Matrix-induced Chondrogenesis Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Autologous Matrix-induced Chondrogenesis Historic Market Size by Type (2016-2021)
2.3 Global Autologous Matrix-induced Chondrogenesis Forecasted Market Size by Type (2022-2027)
2.4 Hyaluronic Acid
2.5 Collagen
2.6 Polyethylene Glycol (PEG)
2.7 Poly Lactic-Co-Glycolic Acid (PGLA)

3 Autologous Matrix-induced Chondrogenesis Market Overview by Application
3.1 Global Autologous Matrix-induced Chondrogenesis Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Autologous Matrix-induced Chondrogenesis Historic Market Size by Application (2016-2021)
3.3 Global Autologous Matrix-induced Chondrogenesis Forecasted Market Size by Application (2022-2027)
3.4 Knees Joint
3.5 Other

4 Autologous Matrix-induced Chondrogenesis Competition Analysis by Players
4.1 Global Autologous Matrix-induced Chondrogenesis Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Autologous Matrix-induced Chondrogenesis as of 2020)
4.3 Date of Key Players Enter into Autologous Matrix-induced Chondrogenesis Market
4.4 Global Top Players Autologous Matrix-induced Chondrogenesis Headquarters and Area Served
4.5 Key Players Autologous Matrix-induced Chondrogenesis Product Solution and Service
4.6 Competitive Status
4.6.1 Autologous Matrix-induced Chondrogenesis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles and Key Data
5.1 JRI Orthopaedics Ltd
5.1.1 JRI Orthopaedics Ltd Profile
5.1.2 JRI Orthopaedics Ltd Main Business
5.1.3 JRI Orthopaedics Ltd Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.1.4 JRI Orthopaedics Ltd Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.1.5 JRI Orthopaedics Ltd Recent Developments
5.2 BioTissue
5.2.1 BioTissue Profile
5.2.2 BioTissue Main Business
5.2.3 BioTissue Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.2.4 BioTissue Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.2.5 BioTissue Recent Developments
5.3 Anika Therapeutics
5.3.1 Anika Therapeutics Profile
5.3.2 Anika Therapeutics Main Business
5.3.3 Anika Therapeutics Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.3.4 Anika Therapeutics Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.3.5 B. Braun Melsungen Recent Developments
5.4 B. Braun Melsungen
5.4.1 B. Braun Melsungen Profile
5.4.2 B. Braun Melsungen Main Business
5.4.3 B. Braun Melsungen Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.4.4 B. Braun Melsungen Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.4.5 B. Braun Melsungen Recent Developments
5.5 Arthro-Kinetics
5.5.1 Arthro-Kinetics Profile
5.5.2 Arthro-Kinetics Main Business
5.5.3 Arthro-Kinetics Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.5.4 Arthro-Kinetics Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.5.5 Arthro-Kinetics Recent Developments
5.6 Geistlich Pharma
5.6.1 Geistlich Pharma Profile
5.6.2 Geistlich Pharma Main Business
5.6.3 Geistlich Pharma Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.6.4 Geistlich Pharma Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.6.5 Geistlich Pharma Recent Developments
5.7 CartiHeal
5.7.1 CartiHeal Profile
5.7.2 CartiHeal Main Business
5.7.3 CartiHeal Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.7.4 CartiHeal Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.7.5 CartiHeal Recent Developments
5.8 Matricel
5.8.1 Matricel Profile
5.8.2 Matricel Main Business
5.8.3 Matricel Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.8.4 Matricel Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.8.5 Matricel Recent Developments
5.9 Smith & Nephew
5.9.1 Smith & Nephew Profile
5.9.2 Smith & Nephew Main Business
5.9.3 Smith & Nephew Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.9.4 Smith & Nephew Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.9.5 Smith & Nephew Recent Developments
5.10 Zimmer Biomet Holdings
5.10.1 Zimmer Biomet Holdings Profile
5.10.2 Zimmer Biomet Holdings Main Business
5.10.3 Zimmer Biomet Holdings Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.10.4 Zimmer Biomet Holdings Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2016-2021)
5.10.5 Zimmer Biomet Holdings Recent Developments

6 North America
6.1 North America Autologous Matrix-induced Chondrogenesis Market Size by Country (2016-2027)
6.2 United States
6.3 Canada

7 Europe
7.1 Europe Autologous Matrix-induced Chondrogenesis Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe

8 Asia-Pacific
8.1 Asia-Pacific Autologous Matrix-induced Chondrogenesis Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific

9 Latin America
9.1 Latin America Autologous Matrix-induced Chondrogenesis Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America

10 Middle East & Africa
10.1 Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa

11 Autologous Matrix-induced Chondrogenesis Market Dynamics
11.1 Autologous Matrix-induced Chondrogenesis Industry Trends
11.2 Autologous Matrix-induced Chondrogenesis Market Drivers
11.3 Autologous Matrix-induced Chondrogenesis Market Challenges
11.4 Autologous Matrix-induced Chondrogenesis Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
  • FORMAT: PDF
  • PUBLISHED DATE: Jun, 2021
  • NO OF PAGES: 140